ESR1 and breast carcinoma: Notably, it has been suggested that direct blockade of AKT may provide a better treatment option for endocrine-resistant breast cancer, affecting cell survival and ER ligand-independent signaling in both PIK3CA-mutant and wild-type tumors18.